Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16744
Title: Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive decline
Austin Authors: Ayton, Scott;Fazlollahi, Amir;Bourgeat, Pierrick;Raniga, Parnesh;Ng, Amanda;Lim, Yen Ying;Diouf, Ibrahima;Farquharson, Shawna ;Fripp, Jurgen;Ames, David;Doecke, James D;Desmond, Patricia;Ordidge, Roger;Masters, Colin L ;Rowe, Christopher C ;Maruff, Paul;Villemagne, Victor L ;Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group;Salvado, Olivier;Bush, Ashley I
Affiliation: Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Queensland, Australia
Cooperative Research Centre for Mental Health, Parkville, Victoria, Australia
Department of Anatomy and Neuroscience, The University of Melbourne, Parkville, Victoria, Australia
National Ageing Research Institute, Parkville, Victoria, Australia
University of Melbourne Academic Unit for the Psychiatry of Old Age, Parkville, Victoria, Australia
Department of Medicine and Radiology, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
Austin Health, Heidelberg, Victoria, Australia
Cogstate Ltd, Melbourne, Victoria, Australia
Issue Date: 24-Jul-2017
metadata.dc.date: 2017-07-24
Publication information: Brain 2017; 140(8): 2112-2119
Abstract: See Derry and Kent (doi:10.1093/awx167) for a scientific commentary on this article. The large variance in cognitive deterioration in subjects who test positive for amyloid-β by positron emission tomography indicates that convergent pathologies, such as iron accumulation, might combine with amyloid-β to accelerate Alzheimer’s disease progression. Here, we applied quantitative susceptibility mapping, a relatively new magnetic resonance imaging method sensitive to tissue iron, to assess the relationship between iron, amyloid-β load, and cognitive decline in 117 subjects who underwent baseline magnetic resonance imaging and amyloid-β positron emission tomography from the Australian Imaging, Biomarkers and Lifestyle study (AIBL). Cognitive function data were collected every 18 months for up to 6 years from 100 volunteers who were either cognitively normal (n = 64) or diagnosed with mild cognitive impairment (n = 17) or Alzheimer’s disease (n = 19). Among participants with amyloid pathology (n = 45), higher hippocampal quantitative susceptibility mapping levels predicted accelerated deterioration in composite cognition tests for episodic memory [β(standard error) = −0.169 (0.034), P = 9.2 × 10−7], executive function [β(standard error) = −0.139 (0.048), P = 0.004), and attention [β(standard error) = −0.074 (0.029), P = 0.012]. Deteriorating performance in a composite of language tests was predicted by higher quantitative susceptibility mapping levels in temporal lobe [β(standard error) = −0.104 (0.05), P = 0.036] and frontal lobe [β(standard error) = −0.154 (0.055), P = 0.006]. These findings indicate that brain iron might combine with amyloid-β to accelerate clinical progression and that quantitative susceptibility mapping could be used in combination with amyloid-β positron emission tomography to stratify individuals at risk of decline.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16744
DOI: 10.1093/brain/awx137
ORCID: 0000-0002-2605-4766
0000-0003-3910-2453
0000-0001-8259-9069
Type: Journal Article
Subjects: Quantitative Susceptibility Mapping
MRI
iron
Alzheimer’s
Cognitive decline
Appears in Collections:Journal articles

Show full item record

Page view(s)

8
checked on Nov 30, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.